Effectiveness of corticosteroid injections in adhesive capsulitis of shoulder: A meta-analysis

Wei Wang, MD, Mingmin Shi, MD, Chenhe Zhou, MD, Zhongli Shi, MD, Xunzi Cai, MD, Tiao Lin, MD, Shigui Yan, MD

Abstract

Background: Primary adhesive capsulitis is mainly characterized by spontaneous chronic shoulder pain and the gradual loss of shoulder motion. The main treatment for adhesive capsulitis is a trial of conservative therapies, including analgesia, exercise, physiotherapy, oral nonsteroidal anti-inflammation drugs, and intra-articular corticosteroid injections. Previously, it was reported that intra-articular corticosteroid lead to fast pain relief and improvement of range of motion (ROM). The objective of this study was to determine whether corticosteroid injections would lead to better pain relief and greater improvement in ROM.

Methods: We searched PubMed, Medline, and the Cochrane library. We included 5 articles of the 1166 articles identified. Totally injection group included 115 patients and placebo group included 110 patients. We calculated the weighted mean differences to evaluate the pain relief as the primary outcome. We determined the ROM as the secondary outcome. Study quality was evaluated using the 12-item scale. We also used the criteria of the Grading of Recommendations Assessment, Development and Evaluation to evaluate the quality of evidence.

Results: In total, 5 studies were included, 4 of which were randomized clinical trials, with a sample size of 225 patients with adhesive capsulitis of the shoulders. The overall pooled data demonstrated that, compared with placebo as control treatment, intra-articular corticosteroid injections were more effective in reducing the pain score at 0 to 8 weeks, but there was no difference between the injection group and the control group at 9 to 24 weeks. Improvement of ROM in the injection group was greater than that of the control group both at 0 to 8 and 9 to 24 weeks.

Conclusions: Intra-articular corticosteroid injections were more effective in pain relief in the short term, but this pain relief did not sustain in the long term. Intra-articular corticosteroid injection resulted in greater improvement in passive ROM both in the short and the long terms.

Abbreviations: ACS = adhesive capsulitis of the shoulder, GRADE = Grading of Recommendations Assessment, Development and Evaluation, ITT = intention-to-treat, NSAIDs = nonsteroidal anti-inflammation drugs, RCTs = randomized-controlled trials, ROM = range of motion, VAS = visual analog score, WMD = weighted mean differences.

Keywords: adhesive capsulitis of the shoulder, corticosteroid injection, pain, range of motion

1. Introduction

Primary adhesive capsulitis of the shoulder (ACS), or “frozen shoulder,” is an inflammation of articular capsule which is usually aseptic. It was first introduced by Duplay in 1896.\(^1\) It is mainly characterized by spontaneous chronic shoulder pain and gradual loss of shoulder motion including all active and passive movements.\(^2\) The pathogenesis of primary adhesive capsulitis remains unclear.\(^3\) Patients with adhesive capsulitis first encounter a phase of “freezing” when increasing pain and stiffness last for several months, followed by a steady-state stage of “frozen” when shoulder motion is lost, then progressing into a “thawing” phase which presents less pain and return of the restricted motion.\(^4,5\) Although adhesive capsulitis is thought to be self-limited, complete resolution of the pain and disability does not always occur. Only 59% of the patients regain normal function after 4 years.\(^6\) The main treatment for adhesive capsulitis is a trial of conservative therapies, including analgesia, exercise, physiotherapy, oral nonsteroidal anti-inflammation drugs (NSAIDs), and intra-articular corticosteroid injections.\(^7\) It was previously reported that intra-articular corticosteroids lead to fast pain relief and improvement of range of motion (ROM).\(^8-12\)

Buchbinder et al\(^{13}\) performed a systematic review of randomized and pseudo-randomized trials of corticosteroid
injections for shoulder pain, and their conclusion was that corticosteroid injections may be effective. Gresser et al[14] performed a systematic review of randomized-controlled trials (RCTs) and concluded that intra-articular corticosteroid injections lead to greater improvements in pain relief and ROM both in the short and the long terms, but compared to other treatments, the effects were similar in the long term. Sun et al have comparing Steroid injection with Nonsteroidal Anti-inflammatory Agents (NSAIDs)[15] and physiotherapy[16] for shoulder pain and concluded that steroid injection and physiotherapy were equally effective for patients with ACS and provided slightly more improvement in shoulder function without superiority in pain relief or risk of complications at 4 to 6 weeks comparing with NSAIDs. However, the effects of intra-articular injections comparing with placebo for ACS remained unclear. Therefore, we performed a meta-analysis comparing patients with adhesive capsulitis treated with intra-articular injections of corticosteroid and placebo to determine whether corticosteroid injections would lead to better pain relief and greater improvement in ROM. We also asked whether the efficacy of corticosteroid injections is different in the short and long terms.

2. Materials and methods

2.1. Study design

A meta-analysis and systematic review was conducted according to predefined guidelines provided by Cochrane Collaboration (2008) as described previously.[15,16] All data were reported according to the Quality of Reporting for Meta-analysis provided by the Handbook for Systematic Reviews of Intervention Version 5.3.[17]

2.2. Literature research

We searched Electronic databases (PubMed, Web of Science, and the Cochrane library) with the following keywords: Duplay disease, bursitis, capsulitis, frozen shoulder, stiff shoulder, periarthritis, intra-articular injection, and corticosteroid. All the databases were searched by 2 independent investigators (MS and WW), which was last updated on April 25, 2016. Reference lists of all the selected articles were hand-searched for any additional trials (Fig. 1). All analyses were based on previous published studies. Therefore, no ethical approval and patient consent are required.

2.3. Inclusion and exclusion criteria

The literature search initially yielded 1166 relevant trials, which is combined from PubMed (N=952), Web of Science (N=473), and the Cochrane library (N=49) with 308 duplicates excluded. Two of us (ZS and SY) reviewed the titles and abstracts of all 1166 trials. We included those in which the target population consisted of patients undergoing primary adhesive capsulitis, the intervention was intra-articular injection of corticosteroid, the control procedure was sham injection, oral medications or no procedure, the outcomes included pain score and ROM, and the trial was an RCT or prospective, nonrandomized, controlled trials. Trials were excluded if they were Phase I or observational studies, case reports, or reviews, both data of pain score and ROM were unavailable, and the RCTs had a follow-up <2 weeks. By reading the titles and abstracts of these 1166 studies, we excluded 1151 because they did not fulfill the selection criteria. By reading the full text of the 15 remaining articles, 6 used only other procedures as a control (local analgesia, exercise, physiotherapy, etc.), 2 did not report available data regarding pain relief or ROM, 1 was a retrospective controlled trial, and 1 assess the efficacy of intra-articular corticosteroid injection in diabetic patients. Ultimately, 5 prospective controlled trials were included in our meta-analysis, of which 4 were RCTs[11,18-20] and 1 was prospective nonrandomized trials.[9]

The relevant data were extracted from each eligible trials by 2 authors (MS and WW) independently. We also reviewed study design, intervention protocol, sample size, duration of follow-up, outcome measurement, and loss to follow-up. Intention-to-treat (ITT) data were used whenever possible. If the data were not available, we used the data analyzed from the available data or data from the analysis of treatment received. When the data were not reported in the original article, data were extrapolated from the accompanying illustrations. We recorded the characteristics of the 5 included trials (Table 1). The weighted kappa for agreement on eligibility between reviewers was 0.86 (95% confidence interval [CI], 0.78–0.94).

2.4. Methodological quality assessment

Two reviewers (SY and WW) independently assessed the methodological quality of the included trials with a 12-item scale, assessing factors such as randomization, allocation concealment, similar baseline, blinding, selective reporting, patient’s compliance, loss to follow-up, similar timing, and ITT analysis,[21] and we resolved disagreements through discussion (Table 2). The weighted kappa for the agreement on the trial quality between reviewers was 0.88 (95% CI, 0.78–0.99). We also used the criteria of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) to evaluate the quality of the evidence.[22]

2.5. Outcome measures

The visual analog score (VAS) pain scores[23,24] evaluated with credible measurement in the short term and long term after treatment were our primary outcome. We considered the ROM as our secondary outcome. Passive shoulder motion includes abduction, flexion, extension, and rotation (internal rotation and external rotation), and the included studies mostly used abduction, flexion, internal rotation, and external rotation, which were analyzed in our review. We defined the follow-up as a “short-term” follow-up of which duration was <8 weeks and of which more than 8 weeks but <24 as a “long-term” one.

2.6. Statistical analysis

The data were pooled using Review Manager 5.1.3 software (The Cochrane Collaboration, Oxford, UK). All continuous outcome measures were converted to weighted mean differences and the statistical heterogeneity was calculated with a chi-squared test on N – 1 degree of freedom (N=sample size). The inconsistency was also assessed using the formula: (Q = df)/Q × 100% (Q= the chi-squared statistic; df= degree of freedom) to describe the percentage of the variability in effect estimates attributable to the heterogeneity. The F values of 75%, 50%, and 25% were considered as high, medium, and low heterogeneity, respectively. If there were no statistical heterogeneity among the studies, a fixed-effects model was used, otherwise, the random-effects model was used.

We did not make a funnel plots analyses because the number of studies were limited. Sensitivity analyses were performed to evaluate whether specified factors could
influence the overall effects of pain scoring and ROM. We omitted the studies one by one, which is nonrandomized, or with small sample size and using oral medications as control treatment.

3. Results
A total of 1166 eligible articles were revealed in our study, among which we rejected 1151 articles according the title and abstract. We reviewed the remained 15 studies for full papers. We further excluded

| Table 1: Characteristics of the included studies. |
|-----------------------------------------------|
| **RCTs** | **Intervention/comparison groups** | **Injection technique** | **Sample size, CI/PLB** | **Follow-up, wk** | **Outcome measurement** | **Loss to follow-up, %** |
| Bal et al[18] | CI: 40 mg methylprednisolone acetate; PLB: saline solution | Injections under fluoroscopic guidance, posterior approach, single injection | 40/40 | 12 | Night pain score, ROM, SPADI | 20 |
| Carette et al[19] | CI: 40 mg triamcinolone; PLB: saline solution | Fluoroscopic guided intra-articular injection, single injection | 25/23 | 48 | SPADI, ROM, SF-36 | 18.7 |
| Bulgen et al[20] | CI: 40 mg triamcinolone; PLB: saline solution | Blinded anterior route, weekly, for 3 wk | 11/8 | 24 | Pain score, ROM | 0 |
| Ryans et al[21] | CI: 20 mg triamcinolone; PLB: saline solution | Half the solution was injected by an anterior approach and half by a lateral approach without imaging guidance, single injection | 19/19 | 16 | Pain score, ROM, SDQ | 5.20 |
| Lorbach et al[9] | CI: 40 mg triamcinolone; PLB: no injection but oral 40 mg triamcinolone every 5 d | Fluoroscopic guided intra-articular injection, single injection | 20/20 | 48 | Constant score, VAS (pain, function, and satisfactions), SF-36, ROM | 0 |

CI = corticosteroid injection, PLB = placebo, RCTs = randomized-controlled trials, ROM = range of motion, SDQ = self-description questionnaire, SF-36 = short form-36, SPADI = shoulder pain and disability index, VAS = visual analog score.
10 unsuitable articles based on our inclusive and exclusive criteria. Finally we included 4 RCTs and 1 prospective, nonrandomized, controlled trial in this meta-analysis. A flow chart is shown in Fig. 1.

3.1. Pain relief in short term and long term

Compared with control treatment, intra-articular corticosteroid injections were more effective in reducing the pain score \( P < .001 \) at 0 to 8 weeks (Fig. 2). However, there was no difference between the injection group and the control group at 9 to 24 weeks \( (P = .92) \). The resulting pain scores at different times had a low heterogeneity \( (0-8 \text{ weeks: } I^2 = 0\% \); \( 9-24 \text{ weeks: } I^2 = 50\% \)\). The overall results of pain score analyses were not changed by omitting the trial, which consisted of a small sample size and used oral medications as the control treatment\(^{11}\) (Table 3).

3.2. ROM in short term and long term

Improvement of ROM in the injection group was assessed by the range of abduction, flexion, external rotation, and internal rotation greater. The range of abduction both at 0 to 8 and 9 to 24 weeks in the injection group was greater than in the control group \( (0-8 \text{ weeks: } P < .001 \); \( 9-24 \text{ weeks: } P < .001 \); Fig. 3). Compared with the control group, there was greater improvement in the range of flexion both in the short- and long-term follow-up \((0-8 \text{ weeks: } P < .001 \); \( 9-24 \text{ weeks: } P < .001 \); Fig. 4). The range of external rotation both at 0 to 8 and 9 to 24 weeks for the injection group was greater than in the control group \( (0-8 \text{ weeks: } P < .001 \); \( 9-24 \text{ weeks: } P = .002 \); Fig. 5). Compared with the control group, there was greater improvement in the range of internal rotation at 0 to 8 weeks \( (P < .001) \), but there was no difference at 9 to 24 weeks \( (P = .37) \); Fig. 6). Most of these analyses had no or low heterogeneity \( (\text{abduction: } 0-8 \text{ weeks: } I^2 = 12\%; \ 9-24 \text{ weeks: } I^2 = 0\%; \text{ flexion: } 0-8 \text{ weeks: } I^2 = 0\%; \ 9-24 \text{ weeks: } I^2 = 0\%; \text{ external rotation: } 0-8 \text{ weeks: } I^2 = 40\%; \ 9-24 \text{ weeks: } I^2 = 0\% \). The overall results of ROM analyses were not changed by omitting the trial,
which was nonrandomized, or consisted of a small sample size and included the use of oral medications as the control treatment.

4. Discussion

This literature review of existing RCT and of prospective, nonrandomized, controlled trials revealed that intra-articular corticosteroid injections resulted in improvement of clinical outcome measures of ACS based on VAS pain scores and ROM, but this improvement was different in the short-term and the long-term follow-up. At 0 to 8 weeks of follow-up, both of VAS pain scores and ROMs were improved by intra-articular corticosteroid injection when compared with the control group. However, at 9 to 24 weeks of follow-up, the ROMs had improved but there was no difference between the injection and control treatment in VAS pain scores.

4.1. Limitations

Our meta-analysis has some limitations. First, due to the limited number of included trials, we could not analyze the influence of other clinically relevant factors, such as the baseline severity of shoulder pain, initial and additional medications, and dosage of corticosteroids. Second, missing information such as loss to follow-up led to incomplete data and potential bias. Third, the small sample sizes and moderate methodological qualities of some included studies might cause bias in our meta-analysis. However, by omitting these 2 trials, the results for the overall analysis of pain relief and ROMs were not changed.

A previous systematic review of 8 studies evaluated the effects of intra-articular corticosteroid injections on ACS. Of these, 3 studies compared the intra-articular corticosteroid injections to placebo. Our review was the first to attempt to include all the available prospective evidence comparing intra-articular corticosteroid injections and placebo. We developed explicit inclusion and exclusion criteria.

According to the GRADE system of rating quality of evidence, most of the included trials reviewed in this meta-analysis began with moderate-quality evidence, but were downgraded by 5 categories of limitations (Table 4). Insufficient participants in most studies may cause limitations, and adequate sequence generation, randomization, and blinding may lead to potential bias.

Table 3

| WMD (95% CI) | Pain score | Abduction | Flexion | Ext. rotation | Int. rotation |
|-------------|------------|-----------|---------|--------------|--------------|
| Omitting studies | | | | | |
| 0–8 wk | Bulgen et al. | NA | 12.30 (9.97, 18.63) | 14.68 (8.11, 23.24) | 11.59 (6.61, 17.59) | NA |
| | P | NA | .0051 | .0008 | <.0001 | NA |
| | Lorbach et al. | -.18.46 (-26.62, -10.29) | 11.48 (9.06, 17.91) | 11.53 (4.75, 18.31) | 8.78 (4.23, 13.33) | 25.00 (14.04, 35.96) |
| | P | <.0001 | .0005 | .0009 | .0002 | <.00001 |
| 9–24 wk | Bulgen et al. | NA | 12.71 (8.87, 18.55) | 12.71 (8.87, 18.55) | 8.46 (4.55, 15.36) | NA |
| | P | NA | <.0001 | <.0001 | NA | NA |
| | Lorbach et al. | 0.53 (-10.38, 11.44) | 12.07 (8.14, 18.01) | 12.07 (8.14, 18.01) | 10.66 (2.87, 18.45) | 0.00 (-11.17, 11.17) |
| | P | 1.00 | <.0001 | <.0001 | .007 | <.00001 |

Data were not reported in the original article, and the author did not supply the original data after being asked for, and we could not extrapolate them from the accompanying illustrations.

CI = confidence interval, Ext. = external, Int. = internal, NA = not available, ROM = range of motion, WMD = weighted mean difference.

Figure 3. Forest plot for range of abduction at (A) 0 to 8 weeks and (B) 9 to 24 weeks. The range of abduction both at 0 to 8 and 9 to 24 weeks in the injection group was greater than in the control group (0–8 weeks: P < .0003; 9–24 weeks: P < .0001). CI = intra-articular corticosteroid injection group, PLB = placebo group.
allocation concealment, and blinding were described explicitly, which could make the limitation not serious. The main reason to downgrade the level of evidence was that the imprecision probably resulted from the small sample sizes. Thus, the present conclusion regarding the efficacy of intra-articular corticosteroid injections on adhesive capsulitis should be considered with caution.

Intra-articular steroid injections have been recommended in ACS based on the fact that it can diminish the inflammation that is thought to be the cause for the condition. There has been controversy regarding the ability of intra-articular corticosteroid injections to relieve pain and restore function in patients with adhesive capsulitis in the short term and the long term. In

![Forest plot for range of flexion at (A) 0 to 8 weeks and (B) 9 to 24 weeks.](image1)

- Compared with control group, there was greater improvement in the range of flexion both in the short-term and long-term follow-ups (0–8 weeks: \( P < .0001 \); 9–24 weeks: \( P < .0001 \)). CI = intra-articular corticosteroid injection group, PLB = placebo group.

![Forest plot for range of external rotation at (A) 0 to 8 weeks and (B) 9 to 24 weeks.](image2)

- The range of external rotation both at 0 to 8 and 9 to 24 weeks in the injection group was greater than in the control group (0–8 weeks: \( P = .0002 \); 9–24 weeks: \( P = .002 \)). CI = intra-articular corticosteroid injection group, PLB = placebo group.
our meta-analysis, intra-articular corticosteroid injections were more effective in pain relief in the short term, but this pain relief did not sustain in the long term. In addition, intra-articular corticosteroid injections resulted in greater improvement in passive ROM both in the short and the long terms. However, the duration of follow-up was short after treatment in this study (maximum, 24 weeks). The natural history of adhesive capsulitis shows that most patients achieve the maximal outcome between 2 and 4 years after treatment. On the other hand, some studies have demonstrated severe loss of shoulder motion, mild residual pain, disability of activities of daily living, and weakness at longer-term follow-up (as long as 7 years). Numerous authors have reported that complete resolution is not inevitable. In a well-conducted study of 62 patients, 50% of the patients continued to have either mild pain or stiffness of the shoulder after 7 years. According to our analysis, the use of intra-articular corticosteroid injections, significantly improved ROM in the corticosteroid injection group, both in the short term and long term, which indicates that intra-articular corticosteroid injections are beneficial for the patients’ functional recovery. In addition, intra-articular corticosteroid injections resulted in fast pain relief. However, the pain relief did not last in the long term. These data suggested that intra-articular corticosteroid injections are helpful for pain relief in only the short term.

5. Conclusions
In summary, intra-articular corticosteroid injections were more effective in pain relief in the short term. Unfortunately, this pain

---

**Figure 6.** Forest plot for range of internal rotation at (A) 0 to 8 weeks and (B) 9 to 24 weeks. Compared with control group, there was greater improvement in the range of internal rotation at 0 to 8 weeks ($P = 0.0001$), but there was no difference at 9 to 24 weeks ($P = 0.37$). CI = intra-articular corticosteroid injection group, PLB = placebo group.

**Table 4**
GRADE evidence profile of analyses.

| Outcome          | Time, wk | Number (treated/control) | WMD (95% CI), g/cm² | Risk of bias¹ | Inconsistency² | Indirectness | Imprecision³ | Others⁴ | Quality |
|------------------|----------|--------------------------|----------------------|---------------|----------------|--------------|--------------|---------|---------|
| Pain score       | 0–8      | 4 (85/77)                | −16.30 (±23.65, −8.94) | Not serious   | Not serious    | Not serious  | Serious       | None    | Moderate |
|                  | 9–24     | 4 (85/77)                | 0.53 (±10.38, 1.44)  | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
| Abduction        | 0–8      | 4 (91/96)                | 12.78 (±6.63, 18.93) | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
|                  | 9–24     | 4 (91/96)                | 11.95 (±6.36, 17.54) | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
| Flexion          | 0–8      | 4 (91/96)                | 13.80 (±7.58, 20.03) | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
|                  | 9–24     | 4 (91/96)                | 11.95 (±5.36, 17.54) | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
| External rotation| 0–8      | 5 (110/115)              | 9.79 (±5.56, 14.01)  | Not serious   | Not serious    | Not serious  | Serious       | None    | Moderate |
|                  | 9–24     | 5 (110/115)              | 10.59 (±4.05, 17.14) | Not serious   | Not serious    | Not serious  | Not serious   | None    | Moderate |
| Internal rotation| 0–8      | 2 (80/80)                | 15.38 (±3.24, 33.99) | Serious       | Serious        | Not serious  | Not serious   | None    | Low     |
|                  | 9–24     | 2 (80/80)                | 3.11 (±3.75, 9.98)   | Serious       | Serious        | Not serious  | Not serious   | None    | Low     |

CI = confidence interval, GRADE = Grading of Recommendations Assessment, Development and Evaluation, WMD = weighted mean difference.

¹ Inadequate blinding, lack of allocation concealed in some trials may increase risk of bias.

² Inconsistent report of outcomes and significant heterogeneity existed across the trials.

³ If a study has a wide confidence interval around the estimate of the effect, or included patients <400, it may cause imprecision.

⁴ “Other” consisted of publication bias and upgraded quality of evidence (large effect, plausible residual confounding, and dose–response gradient).

---
relief did not last in the long term. Intra-articular corticosteroid injections resulted in greater improvement of passive ROM both in the short and the long terms.

**Acknowledgment**

The authors wish to thank all the corresponding authors from the included trials for their kind assistance in obtaining additional data that contributed to our meta-analysis.

**References**

[1] De SD. La periarthrite scapulohumérale. Rev Frat D Trav De Med 1996;53:226.
[2] Grey RG. The natural history of “idiopathic” frozen shoulder. J Bone Joint Surg Am 1978;60:564.
[3] Bunker TD, Anthony PP. The pathology of frozen shoulder. A Dupuytren-like disease. J Bone Joint Surg Br 1995;77:677–83.
[4] Owe CRLR. Rowe CR. Idiopathic chronic adhesive capsulitis (“frozen shoulder”), The Shoulder Churchill Livingstone, New York, NY:1988.
[5] Miller MD, Wirth MA, Rockwood CJ. Thawing the frozen shoulder: the effectiveness of corticosteroid injections. J Shoulder Elbow Surg 2010;19:172–8.
[6] Favejee MM, Huissi Stede BM, Koes BW. Frozen shoulder: the effectiveness of conservative and surgical interventions—systematic review. Br J Sports Med 2011;45:49–56.
[7] Neviser AS, Hannafin JA. Adhesive capsulitis: a review of current treatment. Am J Sports Med 2010;38:2346–56.
[8] van der Windt DA, Koes BW, Deville W, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ 1998;317:1292–6.
[9] Lorbach O, Anagnostakos K, Scherf C, et al. Nonoperative management of adhesive capsulitis of the shoulder: oral cortisone application versus intra-articular cortisone injections. J Shoulder Elbow Surg 2010;19:172–9.
[10] Jacobs LG, Smith MG, Khan SA, et al. Manipulation or intra-articular steroids in the management of adhesive capsulitis of the shoulder? A prospective randomized trial. J Shoulder Elbow Surg 2009;18:348–53.
[11] Ryans I, Montgomery A, Galway R, et al. A randomized controlled trial of intra-articular triamcinolone and/or physiotherapy in shoulder capsulitis. Rheumatology (Oxford) 2005;44:529–35.
[12] Arslan S, Celiker R. Comparison of the efficacy of local corticosteroid injection and physical therapy for the treatment of adhesive capsulitis. Rheumatol Int 2001;21:20–3.
[13] Bucchinder R, Green S, Youd JM. Corticosteroid injections for shoulder pain. Cochrane Database Syst Rev 2003;(1):CD004016.
[14] Griesser MJ, Harris JD, Campbell JE, et al. Adhesive capsulitis of the shoulder: a systematic review of the effectiveness of intra-articular corticosteroid injections. J Bone Joint Surg Am 2011;93:1727–33.
[15] Sun Y, Chen J, Li H, et al. Steroid injection and nonsteroidal anti-inflammatory agents for shoulder pain: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2015;94:e2216.
[16] Sun Y, Lu S, Zhang P, et al. Steroid injection versus physiotherapy for patients with adhesive capsulitis of the shoulder: a PRISMA systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2016;95:e3469.
[17] Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Rev Esp Salud Publica 2000;74:107–18.
[18] Bal A, Eksoglu E, Gulec B, et al. Effectiveness of corticosteroid injection in adhesive capsulitis. Clin Rehabil 2008;22:503–12.
[19] Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829–38.
[20] Bulgen DY, Binder AI, Hazleman BL, et al. Frozen shoulder: prospective clinical study with an evaluation of three treatment regimes. Ann Rheum Dis 1984;43:353–60.
[21] Furlan AD, Pennick V, Bombardier C, et al. 2009 Updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976) 2009;34:1929–41.
[22] Atkins D, Briss PA, Eccles M, et al. Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res 2005;5:25.
[23] Huskisson EC. Measurement of pain. J Rheumatol 1982;9:768–9.
[24] Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain 1975;1:277–99.
[25] Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539–58.
[26] Hannafin JA, Chiaia TA. Adhesive capsulitis. A treatment approach. Clin Orthop Relat Res 2000;(372):95–109.
[27] Binder AI, Bulgen DY, Hazleman BL, et al. Frozen shoulder: a long-term prospective study. Ann Rheum Dis 1984;43:361–4.
[28] Hand C, Clipsham K, Rees JL, et al. Long-term outcome of frozen shoulder. J Shoulder Elbow Surg 2008;17:231–6.
[29] O’Kane JW, Jackins S, Sidles JA, et al. Simple home program for frozen shoulder to improve patients’ assessment of shoulder function and health status. J Am Board Fam Pract 1999;12:270–7.
[30] Shafter B, Tibone JE, Kerlan RK. Frozen shoulder. A long-term follow-up. J Bone Joint Surg Am 1992;74:738–46.